Tasosartan and nsp15 Activity
Cell-based study · SARS-CoV-2 nsp15 [1]
SARS-CoV-2 nsp15 was preincubated with Tasosartan in DMSO before activity quantification. Tasosartan reduced nsp15 activity, with similar activity observed at the higher concentration.
| Endpoint | Reported result | Reference |
|---|---|---|
| Quantification of nsp15 activity | nsp15 activity nsp15 retained only ~40% of its activity | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 600 and 1000 µM
- Exposure duration
- 7 min at room temperature
- Method
- previously incubated
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: Tasosartan
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Materials and Methods > 2.3. RNase Activity Assays (S38, S41, S42); 3. Results > 3.4. Searching for SARS-CoV-2 nsp15 Inhibitors (S171, S174, S177, S178, S181); Figure 7 legend (S233, S234)
Quantification of nsp15 activity: Quantification of nsp15 activity; comparator: nsp15 in the presence of DMSO — 3. Results > 3.4. Searching for SARS-CoV-2 nsp15 Inhibitors (S178, S181); Figure 7 legend (S233)